Article

Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancer

2022-08-19

Abstract excerpt

<title>Abstract</title> <p>De-escalated or escalated systemic therapy remains to be a controversial topic for HER2-positive early breast cancer. Here we presented a novel assay for predicting the relapse risk and survival in HER2-positive early breast cancer. The prognostic models based on the 20-gene signature (HER2RI model) and 20-gene signature combined with nodal stage (HER2RIclin model) were built using rand...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 134ae9ee-aaea-5fd6-be36-7ed46de86ece
DOI: 10.21203/rs.3.rs-1964372/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancerDOI 10.21203/rs.3.rs-1964372/v1Read

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity Read

Validation of a Clinical-Genomic Model for Patients With Early-Stage Breast Cancer Enrolled in a Taiwanese Multicenter StudySemantic proximity Read

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read

Development of a Prognostic Model for HR-positive HER2-negative and Node-negative Breast Cancer: Integrating Clinical and Transcriptional BiomarkersSemantic proximity Read

Identification of A 10-Gene Signature To Predict Efficacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer.Semantic proximity Read

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentSemantic proximity Read

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast CancerSemantic proximity Read

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read

Impact of Different Modules of 21-Gene Assay in Early Breast Cancer PatientsSemantic proximity Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read

Novel Gene Signatures Predicting Breast Cancer Based on Random Forest and Artificial Neural NetworkSemantic proximity Read